Aquestive Therapeutics, Inc.

AQST

$207M

Micro Cap

NASDAQPharmaceutical Preparations🇺🇸North AmericaWARREN142 employees

Drugs in Pipeline

Phase 3 Programs

Upcoming Catalysts

Next Catalyst

Feb 10, 2026

Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply

Market Overview

Stock performance and market intelligence

Catalyst Timeline

3 upcoming, 1 past

🎯PDUFANext

FDA PDUFA Date AQST-109 (standard)

2/10/2026

For Epinephrine nasal spray for the emergency treatment of allergic reactions. NDA filing. Extracted from SEC filing: 8-K

Source

🎯PDUFA

FDA PDUFA Date AQST-109 (standard)

4/11/2026

For Epinephrine Oral Film. NDA filing. Extracted from SEC filing: 8-K

Source

🎯PDUFA

FDA PDUFA Date EXSERVAN (standard)

4/27/2026

For amyotrophic lateral sclerosis (ALS). NDA filing. Extracted from SEC filing: 8-K

Source

AI Predictions & Institutional Flow

Machine learning insights and smart money movement

FDA Submissions

Pending NDA/BLA submissions with predicted PDUFA dates

Drug Pipeline

Clinical development programs and drug candidates

Drug Pipeline

Diazepam Buccal Soluble Film 5, 7.5,10, 12.5,15 or 17.5 mg with individual dose determined according to age and weight category

Phase 3

Epilepsy

Diazepam Buccal Film 12.5 mg

Phase 2

Epilepsy

Diazepam Buccal Film

Phase 2

Epilepsy

Diastat® Rectal Gel (Valeant Pharmaceuticals USA)

Phase 2

Epilepsy

DESF

Phase 2

Allergic Reaction

Drug Name	Phase	Indication	Designations
Diazepam Buccal Soluble Film 5, 7.5,10, 12.5,15 or 17.5 mg with individual dose determined according to age and weight category	Phase 3	Epilepsy	-
Diazepam Buccal Film 12.5 mg	Phase 2	Epilepsy	-
Diazepam Buccal Film	Phase 2	Epilepsy	-
Diastat® Rectal Gel (Valeant Pharmaceuticals USA)	Phase 2	Epilepsy	-
DESF	Phase 2	Allergic Reaction	-

Regulatory & News

Approvals, filings, and latest developments

Regulatory Approvals

AQST News